A phase ll study of combination therapy with Panitumumab plus CPT-11 for advanced and/or recurrent colon-rectal cancer with wild type KRAS which has prior therapy of fluoropylimidine, oxaliplatin or CPT-11.

Trial Profile

A phase ll study of combination therapy with Panitumumab plus CPT-11 for advanced and/or recurrent colon-rectal cancer with wild type KRAS which has prior therapy of fluoropylimidine, oxaliplatin or CPT-11.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Irinotecan (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 24 Jul 2012 Planned end date changed from 1 Jul 2012 to 31 Jul 2013 as reported by University Hospital Medical Information Network - Japan record.
    • 24 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top